HINGHAM, Mass., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and manufacturer of the innovative LIBERTY® Endovascular Robotic System, announces that its Chief Executive Officer, Harel Gadot, will be interviewed on Benzinga All Access at 10:45am ET on Wednesday, September 24, 2025. The live interview can be viewed at: Benzinga All Access Live. Mr. Gadot will discuss the recent FDA clearance of Microbot Medical’s LIBERTY®, and how the Company has planned for commercializa ...

DENVER, Sept. 23, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company, announced today that preliminary results from the SAVE Surveillance Registry will be presented by SeaStar Medical and its research collaborators at the 5th International Symposium on Acute Kidney Injury in Children. The SAVE Registry presentation will highlight the role of QUELIMMUNE (Selective Cytopheretic Device for Pediatrics, or SCD-PED) therapy in the treatment of critica ...

MINNEAPOLIS--(BUSINESS WIRE)--Agiliti, a leading manufacturer and provider of medical device solutions to the U.S. healthcare industry, has expanded its oncology offerings to physicians and hospitals, providing greater value and access to focal therapy services for diagnosing and treating prostate cancer. "There are approximately 313,000 new prostate cancer cases every year in the U.S., and innovative technologies like HIFU and other focal therapies are an important component of modern care,†e. ...

New program delivers TULSA Procedure’s precision treatment - minimal side effects, no overnight hospital stay – to Medicare patients across TexasTORONTO, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company developing AI-powered, incision-free therapies for ablating diseased tissue, announced today the launch of a first-of-its-kind TULSA program by Texas Prostate and Dallas Medical Center to meet the growing ...

- Patent-pending pre-scan technology enables custom radiation dose tailored to patient’s unique breast size and composition - - Feature aligns with personalized medicine trends driving the global breast imaging device market size to USD $8.69 billion by 2030 - - Integrated into the IzoView commercial model alongside modular engineering, compression-free imaging, and AI-driven image optimization - VANCOUVER, British Columbia, and SACRAMENTO, Calif., Sept. 23, 2025 (GLOBE NEWSWIRE) -- via IBN – Izotropic Corp ...

- Patent-pending pre-scan technology enables custom radiation dose tailored to patient’s unique breast size and composition - - Feature aligns with personalized medicine trends driving the global breast imaging device market size to USD $8.69 billion by 2030 - - Integrated into the IzoView commercial model alongside modular engineering, compression-free imaging, and AI-driven image optimization - VANCOUVER, British Columbia, and SACRAMENTO, Calif., Sept. 23, 2025 (GLOBE NEWSWIRE) -- via IBN – Izotropic Corp ...

Additional New Clinical Data To Be Presented Driving a New Standard of Care in Volume Measurement OAK RIDGE, Tenn., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces it will exhibit at the Heart Failure Society of America (HFSA) Annual Scientific Meeting in Minneapolis, Minnesota, from September 26-29, 2025. The company will debut its newly FDA-cleared, next-generation blood volume analyzer (BVA), signaling a new era of da ...

Johnson & Johnson's (NYSE:JNJ) market capitalization increased by $63 billion in the past three months, driven by a 17.7% rise in share price.Innovative Medicine sales rose by 2.4%, despite the expiration of Stelara's patent, showcasing the company's resilience and innovation.MedTech sales growth of 6.1%, supported by acquisitions and new product launches, highlights the company's expanding market presence.On September 22, 2025, Johnson Rice upgraded Johnson & Johnson (NYSE:JNJ) to a "Buy" rating, with the ...

Johnson & Johnson will withdraw a device to treat acid reflux disease from markets outside the U.S., Bloomberg News reported on Tuesday, citing a company letter sent to doctors. ...

(Bloomberg) -- Johnson & Johnson is withdrawing a device to treat debilitating acid reflux disease from markets outside the US, a move surgeons warned would set back the available treatment options for sufferers by more than a decade and also impact lung transplant patients. Sales of the Linx Reflux Management System will be stopped outside the US from the end of March, the company said in a letter to doctors dated Sept. 17 seen by Bloomberg. J&J confirmed it was stopping sales in “certain countries,” bas ...